相关实验视频

Updated: Sep 12, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

基于结构的药物设计产生了二甲胺衍生物作为强大的HIV-1非核酸逆转录酶抑制剂

Zhenzhen Zhou¹, Jie Guo¹, Xin Li¹

¹Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P. R. China.

ACS infectious diseases

|August 7, 2025

概括

新型DAPY衍生非核酸逆转录酶抑制剂 (NNRTIs) 已开发用于对抗抗药物耐药的人类免疫缺陷病毒1型 (HIV-1). 化合物19对突变菌株表现出强烈的活性,为下一代HIV-1治疗提供了有希望的新一代治疗方法.

科学领域:

药用化学医学化学
病毒学病毒学
药物设计药物设计

背景情况:

艾滋病毒-1药物耐药性降低了非核酸逆转录酶抑制剂 (NNRTIs) 的有效性.
开发新型的NNRTI对于克服耐药性和提高治疗疗效至关重要.

研究的目的:

通过基于结构的药物设计来设计和合成新的DAPY衍生NNRTIs.
评估针对HIV-1的设计化合物的抗病毒活性和耐药性概况.

主要方法:

基于结构的药物设计,使用K-5a2作为化合物.
抗病毒活性测定对HIV-1野生型和突变菌株的抗病毒活性.
机制研究包括HIV-1逆转录酶抑制试验.
分子对接和MM/GBSA计算以评估结合相互作用.

主要成果:

所有设计的化合物都表现出对HIV-1野生类型 (EC50 = 3.03-21.1 nM) 的强烈活性.
与ETR相比,化合物19在对抗耐药菌株 (EC50 = 5.03-37.7nM) 中显示出更高的疗效.
化合物19强烈抑制HIV-1RT (IC50 = 0.107μM),并表现出稳定的结合NNIBP.

结论:

化合物19是一种非常有前途的NNRTI,对抗药物耐药性HIV-1具有显著的弹性.
这项研究为下一代HIV-1治疗提供了一个新的NRTI候选者.

关键词:

这就是DAPYs.艾滋病病毒-1 艾滋病病毒-1 没有NNRTIs的NNRTI 药物耐药性耐药性药物耐药性碎片混合化杂交化

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...